𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region

✍ Scribed by Jens D Bentzen; Hanne Sand Hansen

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
111 KB
Volume
29
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background.

The aim of this phase II study was to evaluate the antitumor activity and toxicity of a non‐platin–containing regimen with paclitaxel and capecitabine.

Methods.

Fifty patients with recurrent or disseminated squamous cell carcinoma were included in the study. The treatment consisted of paclitaxel 175 mg/m^2^ once every third week and capecitabine 825 mg/m^2^ per oral (p.o.) twice daily (bid) for 2 weeks.

Results.

The overall response rate according to the World Health Organization (WHO) criteria was 42%. Two patients had a complete response (CR), 19 patients had a partial response (PR), 14 patients had no change (NC), 12 patients had progressive disease (PD), and 3 patients were not evaluable (NE). The median survival time was 8 months. Toxicity was very moderate. Only 10% of 315 delivered treatments had to be given in reduced dose or postponed for a week or more.

Conclusions.

The toxicity was low and manageable. The overall response rate was comparable to the commonly used cisplatin/5‐fluorouracil regimen. Β© 2006 Wiley Periodicals, Inc. Head Neck 2007

πŸ“œ SIMILAR VOLUMES

Paclitaxel, cisplatin, and 5-fluorouraci
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck
✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 73 KB πŸ‘ 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi

Time to recurrence of squamous cell carc
Time to recurrence of squamous cell carcinoma of the head and neck
✍ Professor Philip M. Stell πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 403 KB πŸ‘ 2 views

A personal series of 3,215 patients with proven squamous cell carcinoma of the mucosal surfaces of the upper aerodigestive tract is presented. Of these patients, 515 suffered a recurrence of their primary tumor after a course of radiotherapy. The time from the end of radiotherapy to diagnosis of a p

A phase II trial of cisplatin and vinore
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
✍ Enrique Espinosa; Pilar Zamora; Alfredo MillΓ‘; Serafin Morales; Raquel Molina; M πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv